These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 17154104)

  • 1. [Rheumatoid arthritis and osteoporosis: trends in their treatments].
    Tanaka Y
    Nihon Rinsho; 2006 Dec; 64(12):2359-66. PubMed ID: 17154104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Secondary osteoporosis UPDATE. Rheumatoid arthritis and bone damage: trends in treatment].
    Tanaka Y
    Clin Calcium; 2010 May; 20(5):735-42. PubMed ID: 20445285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent progress of pathogenesis and treatments in rheumatoid arthritis].
    Tanaka Y
    Clin Calcium; 2005 Jul; 15(7):23-8. PubMed ID: 15995292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathologic condition of osteoporosis in rheumatoid arthritis].
    Suwa A; Saito E; Wakabayashi T; Suzuki Y
    Clin Calcium; 2007 Aug; 17(8):1262-6. PubMed ID: 17660625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of interleukin-1 in bone resorption in rheumatoid arthritis.
    Strand V; Kavanaugh AF
    Rheumatology (Oxford); 2004 Jun; 43 Suppl 3():iii10-iii16. PubMed ID: 15150427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Paradigm shift in the treatment of rheumatoid arthritis by biologics].
    Tanaka Y
    Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].
    Tanaka Y
    Clin Calcium; 2010 Oct; 20(10):1545-52. PubMed ID: 20890038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Daily practice using the guidelines for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis].
    Soen S
    Clin Calcium; 2008 Aug; 18(8):1169-75. PubMed ID: 18677056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inflammatory cytokines for osteoclastogenesis].
    Tanaka Y
    Nihon Rinsho; 2005 Sep; 63(9):1535-40. PubMed ID: 16164208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Paradigm shift in the therapy for rheumatoid arthritis and osteoporosis].
    Tanaka Y
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2377-9. PubMed ID: 19149029
    [No Abstract]   [Full Text] [Related]  

  • 12. A new era in rheumatoid arthritis treatment.
    Costello JC; Halverson PB
    WMJ; 2003; 102(7):29-33. PubMed ID: 14711021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
    Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
    Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
    Akiyama Y; Mimura T
    Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
    Suzuki Y
    Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biochemical markers of bone turnover. New aspect. Therapy of rheumatoid arthritis for bone metabolic marker].
    Okada Y; Nawata M; Tanaka Y
    Clin Calcium; 2009 Aug; 19(8):1186-90. PubMed ID: 19638703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of the joint destruction in RA by TNF-blocking agents].
    Kameda H
    Clin Calcium; 2007 Apr; 17(4):553-60. PubMed ID: 17404485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
    Fujikawa K; Kawakami A; Eguchi K
    Nihon Rinsho; 2007 Jul; 65(7):1211-7. PubMed ID: 17642234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.